Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA clears NeuroMetrix Inc wearable technology for over-the-counter use in treatment of chronic pain


Tuesday, 8 Jul 2014 07:00am EDT 

NeuroMetrix Inc:Says its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from U.S. Food and Drug Administration (FDA) for over-the-counter use.Company is in late stage development of a consumer oriented chronic pain treatment product.Says device is based on wearable technology, presently deployed in the company's SENSUS Pain Management System, that utilizes comfortable, non-invasive electrical stimulation of sensory nerves to induce safe and effective pain relief.Says it is lightweight and can be worn during the day while active, and at night while sleeping.This 510(k) clearance allows the Company to market the over-the-counter device through retail distribution channels without a prescription requirement. 

Company Quote

1.82
0.05 +2.82%
4:00pm EDT